Title:
CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL TARGETING MUC1 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/020087
Kind Code:
A1
Abstract:
The present invention relates to a chimeric antigen receptor-modified T cell targeting Muc1 and the use thereof. In particular, the chimeric antigen receptor provided by the present invention, from the N-terminus to the C-terminus, successively comprises a membrane protein signal peptide, a single-chain antibody combating the membrane proximal end of Muc1, a hinge region of more than 50 amino acid residues, a transmembrane region, a co-stimulatory signal molecule intracellular domain and an immunoreceptor tyrosine-based activation motif. The present invention also comprises a T cell expressing the chimeric antigen receptor. The T cell can recognize and bind to the membrane proximal end of the Muc1 antigen, and kill Muc1-positive tumour cells by efficiently activating proliferation and secreting cytokines. The T cell provided by the present invention can be used for the treatment of various Muc1-positive malignant tumours.
Inventors:
QIAN QIJUN (CN)
JIN HUAJUN (CN)
HE ZHOU (CN)
WANG CHAO (CN)
LI LINFANG (CN)
JIN HUAJUN (CN)
HE ZHOU (CN)
WANG CHAO (CN)
LI LINFANG (CN)
Application Number:
PCT/CN2018/097305
Publication Date:
January 31, 2019
Filing Date:
July 27, 2018
Export Citation:
Assignee:
SHANGHAI CELL THERAPY RES INST (CN)
SHANGHAI CELL THERAPY GROUP CO LTD (CN)
SHANGHAI CELL THERAPY GROUP CO LTD (CN)
International Classes:
C07K19/00; A61K39/395; A61P35/04; C12N15/09
Domestic Patent References:
| WO2003089451A2 | 2003-10-30 |
Other References:
MA, YIDONG: "The Killing Effect of MUC1 Chimeric Antigen Receptor-Engineered Jurkat T Cells On Hepatocellular Carcinoma", MASTER'S THESIS OF SOOCHOW UNIVERSITY, 31 December 2015 (2015-12-31)
M A, YIDONG ET AL. ET AL.: "Specific Cytotoxicity of MUC1 Chimeric Antigen Receptor-Engineered Jurkat T Cells Against Hepatocellular Carcinoma", ACADEMIC JOURNAL OF SECOND MILITARY MEDICAL UNIVERSITY, vol. 35, no. 11, 30 November 2014 (2014-11-30)
CAO, LING ET AL.: "Development of Chimeric Antigen Receptor-Modified T Cells for Treatment of Malignances", JOURNAL OF LANZHOU UNIVERSITY (MEDICAL SCIENCES, vol. 41, no. 1, 28 February 2015 (2015-02-28), XP009511198
M A, YIDONG ET AL. ET AL.: "Specific Cytotoxicity of MUC1 Chimeric Antigen Receptor-Engineered Jurkat T Cells Against Hepatocellular Carcinoma", ACADEMIC JOURNAL OF SECOND MILITARY MEDICAL UNIVERSITY, vol. 35, no. 11, 30 November 2014 (2014-11-30)
CAO, LING ET AL.: "Development of Chimeric Antigen Receptor-Modified T Cells for Treatment of Malignances", JOURNAL OF LANZHOU UNIVERSITY (MEDICAL SCIENCES, vol. 41, no. 1, 28 February 2015 (2015-02-28), XP009511198
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC. (CN)
Download PDF: